Basic Information
RNALocate ID: | RLID:11001005 |
RNA Symbol: | hsa-miR-101-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-101-3p |
RNA ID: | miRBase:MIMAT0000099 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001436 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001437 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001438 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001439 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001440 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001441 | Nucleus | GC cell line (MGC-803) | 29872807 |
RLID:01001442 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11001003 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001004 | Exosome | Renal cancer cells | 21670082 |
RLID:11001006 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001007 | Exosome | Serum | 25349172 |
RLID:11001008 | Microvesicle | Plasma | 23077538 |
RLID-D:11000033 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000298 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-101-3p | Diffuse large b cell lymphoma | MNDR-E-MI-02632 |
MNDR | hsa-miR-101-3p | Rheumatic heart diseases | MNDR-E-MI-02633 |
MNDR | hsa-miR-101-3p | Large cell neuroendocrine cancer | MNDR-E-MI-02634 |
MNDR | hsa-miR-101-3p | Medulloblastoma | MNDR-E-MI-02635 |
MNDR | hsa-miR-101-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-02636 |
MNDR | hsa-miR-101-3p | Ovarian clear cell carcinoma | MNDR-E-MI-02637 |
MNDR | hsa-miR-101-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-02638 |
MNDR | hsa-miR-101-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-02639 |
MNDR | hsa-miR-101-3p | Lymphoma | MNDR-E-MI-02640 |
MNDR | hsa-miR-101-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-02641 |
MNDR | hsa-miR-101-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-02642 |
MNDR | hsa-miR-101-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-02643 |
MNDR | hsa-miR-101-3p | Her2-receptor positive breast cancer | MNDR-E-MI-02644 |
MNDR | hsa-miR-101-3p | Triple negative breast cancer | MNDR-E-MI-02645 |
MNDR | hsa-miR-101-3p | Childhood acute lymphoblastic leukemia | MNDR-E-MI-02646 |
MNDR | hsa-miR-101-3p | Dermatomyositis | MNDR-E-MI-02647 |
MNDR | hsa-miR-101-3p | Prostate cancer | MNDR-E-MI-02648 |
MNDR | hsa-miR-101-3p | Chronic lymphocytic leukemia | MNDR-E-MI-02649 |
MNDR | hsa-miR-101-3p | Gastric cancer | MNDR-E-MI-02650 |
MNDR | hsa-miR-101-3p | Gastric lymphoma | MNDR-E-MI-02651 |
MNDR | hsa-miR-101-3p | Alzheimer disease | MNDR-E-MI-02652 |
MNDR | hsa-miR-101-3p | Attention deficit hyperactivity disorder | MNDR-E-MI-02653 |
MNDR | hsa-miR-101-3p | Intracranial aneurysm | MNDR-E-MI-02654 |
MNDR | hsa-miR-101-3p | Urinary bladder cancer | MNDR-E-MI-02655 |
MNDR | hsa-miR-101-3p | Esophageal carcinoma | MNDR-E-MI-02656 |
MNDR | hsa-miR-101-3p | Heart disease | MNDR-E-MI-02657 |
MNDR | hsa-miR-101-3p | Dysautonomia familial | MNDR-E-MI-02658 |
MNDR | hsa-miR-101-3p | Duchenne muscular dystrophy | MNDR-E-MI-02659 |
MNDR | hsa-miR-101-3p | Graves disease | MNDR-E-MI-02660 |
MNDR | hsa-miR-101-3p | Malaria | MNDR-E-MI-02661 |
MNDR | hsa-miR-101-3p | Leukemia | MNDR-E-MI-02662 |
MNDR | hsa-miR-101-3p | Huntington disease | MNDR-E-MI-02663 |
MNDR | hsa-miR-101-3p | Chorea | MNDR-E-MI-02664 |
MNDR | hsa-miR-101-3p | Cardiovascular disease | MNDR-E-MI-02665 |
MNDR | hsa-miR-101-3p | Moyamoya disease | MNDR-E-MI-02666 |
MNDR | hsa-miR-101-3p | Lung cancer | MNDR-E-MI-02667 |
MNDR | hsa-miR-101-3p | Down syndrome | MNDR-E-MI-02668 |
MNDR | hsa-miR-101-3p | Parkinson disease | MNDR-E-MI-02669 |
MNDR | hsa-miR-101-3p | Breast cancer | MNDR-E-MI-02670 |
MNDR | hsa-miR-101-3p | Cancer | MNDR-E-MI-02671 |
MNDR | hsa-miR-101-3p | Squamous cell carcinoma | MNDR-E-MI-02672 |
MNDR | hsa-miR-101-3p | Pancreatic cancer | MNDR-E-MI-02673 |
MNDR | hsa-miR-101-3p | Melanoma | MNDR-E-MI-02674 |
MNDR | hsa-miR-101-3p | Rectum adenocarcinoma | MNDR-E-MI-02675 |
MNDR | hsa-miR-101-3p | Hepatitis B | MNDR-E-MI-02676 |
MNDR | hsa-miR-101-3p | Epithelial ovarian cancer | MNDR-E-MI-02677 |
MNDR | hsa-miR-101-3p | Nephroblastoma | MNDR-E-MI-02678 |
MNDR | hsa-miR-101-3p | Colon cancer | MNDR-E-MI-02679 |
MNDR | hsa-miR-101-3p | Colon adenocarcinoma | MNDR-E-MI-02680 |
MNDR | hsa-miR-101-3p | Familial ovarian cancer | MNDR-E-MI-02681 |
MNDR | hsa-miR-101-3p | Prostate adenocarcinoma | MNDR-E-MI-02682 |
MNDR | hsa-miR-101-3p | Kidney cancer | MNDR-E-MI-02683 |
MNDR | hsa-miR-101-3p | Thyroid adenomas | MNDR-E-MI-02684 |
MNDR | hsa-miR-101-3p | Carcinoma ductal breast | MNDR-E-MI-02685 |
MNDR | hsa-miR-101-3p | Glioblastoma | MNDR-E-MI-02686 |
MNDR | hsa-miR-101-3p | Astrocytoma | MNDR-E-MI-02687 |
MNDR | hsa-miR-101-3p | Glioma | MNDR-E-MI-02688 |
MNDR | hsa-miR-101-3p | Gallbladder cancer | MNDR-E-MI-02689 |
MNDR | hsa-miR-101-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-02690 |
MNDR | hsa-miR-101-3p | Osteosarcoma | MNDR-E-MI-02691 |
MNDR | hsa-miR-101-3p | Liposarcoma | MNDR-E-MI-02692 |
MNDR | hsa-miR-101-3p | Inclusion body myositis | MNDR-E-MI-02693 |
MNDR | hsa-miR-101-3p | Meningioma | MNDR-E-MI-02694 |
MNDR | hsa-miR-101-3p | Liver cancer | MNDR-E-MI-02695 |
MNDR | hsa-miR-101-3p | Gastric adenocarcinoma | MNDR-E-MI-02696 |
MNDR | hsa-miR-101-3p | Cervical squamous cell carcinoma | MNDR-E-MI-02697 |
MNDR | hsa-miR-101-3p | Lung squamous cell carcinoma | MNDR-E-MI-02698 |
MNDR | hsa-miR-101-3p | Non small cell lung carcinoma | MNDR-E-MI-02699 |
MNDR | hsa-miR-101-3p | Lung adenocarcinoma | MNDR-E-MI-02700 |
MNDR | hsa-miR-101-3p | Adrenocortical cancer | MNDR-E-MI-02701 |
MNDR | hsa-miR-101-3p | Bladder urothelial carcinoma | MNDR-E-MI-02702 |
MNDR | hsa-miR-101-3p | Kidney renal clear cell carcinoma | MNDR-E-MI-02703 |
MNDR | hsa-miR-101-3p | Renal clear cell carcinoma | MNDR-E-MI-02704 |
MNDR | hsa-miR-101-3p | Allergic rhinitis | MNDR-E-MI-02705 |
MNDR | hsa-miR-101-3p | Large cell carcinoma | MNDR-E-MI-02706 |
MNDR | hsa-miR-101-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-02707 |
MNDR | hsa-miR-101-3p | Cholangiocarcinoma | MNDR-E-MI-02708 |
MNDR | hsa-miR-101-3p | Esophageal cancer | MNDR-E-MI-02709 |
MNDR | hsa-miR-101-3p | Liver cirrhosis | MNDR-E-MI-02710 |
MNDR | hsa-miR-101-3p | Lung small cell carcinoma | MNDR-E-MI-02711 |
MNDR | hsa-miR-101-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-02712 |
MNDR | hsa-miR-101-3p | Testicular germ cell cancer | MNDR-E-MI-02713 |
MNDR | hsa-miR-101-3p | Bladder transitional cell carcinoma | MNDR-E-MI-02714 |
MNDR | hsa-miR-101-3p | Breast invasive carcinoma | MNDR-E-MI-02715 |
MNDR | hsa-miR-101-3p | Early hepatocellular carcinoma | MNDR-E-MI-02716 |
MNDR | hsa-miR-101-3p | Familiar ovarian carcinoma | MNDR-E-MI-02717 |
MNDR | hsa-miR-101-3p | B-cell lymphoma | MNDR-E-MI-02718 |
MNDR | hsa-miR-101-3p | Rheumatoid arthritis | MNDR-E-MI-02719 |
MNDR | hsa-miR-101-3p | T-cell leukemia | MNDR-E-MI-02720 |
MNDR | hsa-miR-101-3p | Malignant pleural mesothelioma | MNDR-E-MI-02721 |
MNDR | hsa-miR-101-3p | Retinoblastoma | MNDR-E-MI-02722 |
MNDR | hsa-miR-101-3p | Neuroblastoma | MNDR-E-MI-02723 |
MNDR | hsa-miR-101-3p | Chronic myeloid leukemia | MNDR-E-MI-02724 |
MNDR | hsa-miR-101-3p | Hodgkin lymphoma | MNDR-E-MI-02725 |
MNDR | hsa-miR-101-3p | Burkitt lymphoma | MNDR-E-MI-02726 |
MNDR | hsa-miR-101-3p | Crohn disease | MNDR-E-MI-02727 |
MNDR | hsa-miR-101-3p | Neuromyelitis optica | MNDR-E-MI-02728 |
MNDR | hsa-miR-101-3p | Skin cutaneous melanoma | MNDR-E-MI-02729 |
MNDR | hsa-miR-101-3p | Skin melanoma | MNDR-E-MI-02730 |
MNDR | hsa-miR-101-3p | Acute myeloid leukemia | MNDR-E-MI-02731 |
MNDR | hsa-miR-101-3p | Colon and rectal adenocarcinoma | MNDR-E-MI-02732 |
MNDR | hsa-miR-101-3p | Nasopharyngeal carcinoma | MNDR-E-MI-02733 |
MNDR | hsa-miR-101-3p | Ovarian epithelial cancer | MNDR-E-MI-02734 |
MNDR | hsa-miR-101-3p | Ependymoma | MNDR-E-MI-02735 |
MNDR | hsa-miR-101-3p | Nasopharyngeal cancer | MNDR-E-MI-02736 |
MNDR | hsa-miR-101-3p | Stroke lacunar | MNDR-E-MI-02737 |
MNDR | hsa-miR-101-3p | Breast cancer her3+ negative | MNDR-E-MI-02738 |
MNDR | hsa-miR-101-3p | High grade dysplastic nodule | MNDR-E-MI-02739 |
MNDR | hsa-miR-101-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-02740 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022076 |
TOP